Soligenix (NASDAQ:SNGX) is a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. With a robust research pipeline, the firm is currently advancing multiple projects across two distinct areas: BioTherapeutics and Vaccines/BioDefense. Among its notable undertakms are innovative treatments for conditions such as cutaneous T-cell lymphoma, pediatric Crohn’s disease, and acute radiation syndrome. Soligenix's objective is to harness its proprietary technologies and scientific expertise to provide breakthrough therapies for serious health conditions, striving to improve patient outcomes and quality of life.